Live Breaking News & Updates on Biogeneration ventures
Stay updated with breaking news from Biogeneration ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AMSTERDAM, Nov. 16, 2022 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug
Sander van Deventer is co-founder and former Chief Technology Officer of the Company Elena Ritsou assumes role of Chief Corporate Officer Barbara Sanders is promoted to Chief Technology
Synaffix obtains exclusive rights to the CliCr technology, to combine with its proprietary ADC platform technology CliCr further expands the repertoire of payloads suitable for conjugation by
/PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of...
/PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug...
/PRNewswire/ -- Synaffix B.V. (Synaffix) and Emergence Therapeutics AG ("Emergence") ("the Companies") today announce that the Companies have entered into a...
Global oral solid dosage contract manufacturing market recorded sales worth US$ 23.4 Bn in 2021 and is predicted to expand at a CAGR of 5.9% from 2022 to 2032.
Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs Kyowa Kirin also exercises exclusive target option for development...
Dr. Huang brings more than 30 years of biopharma experience, most recently as Chief Executive Officer and President of Flagship Pioneering start-up Cygnal Therapeutics Dunad appoints new CEO